Chinook Therapeutics Inc expected to post a loss of 68  cents a share - Earnings Preview

Chinook Therapeutics

05/05/2021 03:56

* Chinook Therapeutics Inc  KDNY.OQ   KDNY.O  is expected to
show a fall in quarterly revenue when it reports results on May
5 (estimated).
* The Seattle, Washington-based company is expected to report 
 a 99.6% decrease in revenue to $50 thousand from $13.95 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data.
​* Refinitiv's mean analyst estimate for Chinook Therapeutics
Inc is for a loss of 68 cents per share. For the same quarter
last year, the company reported a loss of 45 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had fallen by
about 9.4% in the last three months. ​
* Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $31​, about 42.7% above​ its last closing
price of $17.75. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.51       -0.44      -1.24     Missed  -178.7
 Sep. 30 2020  -0.49       -0.45      -0.90     Missed  -97.8
 Jun. 30 2020  -1.01       -0.95      -1.05     Missed  -10.5​
 Mar. 31 2020  -0.76       -0.67      -0.45     Beat    33.3
 Dec.          -1.07​      -1.05      -1.20     Missed  -13.9​
 31​ 2019​                                              
 Sep. 30 2019  -1.17       -1.16      -1.00     Beat    13.7​
 Jun. 30 2019  -1.15       -0.91      -1.15     Missed  -26.1
 Mar. 31 2019  -0.98       -0.95      -1.45     Missed  -52.9
 This summary was machine generated May 5 at 02:56 GMT.  All
figures in US dollars unless otherwise stated